Weill Cornell's Mateo Mejia Saldarriaga, MD, explains why oral options like iberdomide and clinical trials matter in the immunotherapy era of myeloma.
Myeloma risk prediction is strong, but matching each patient to optimal therapy is still being tested, says Nikhil C. Munshi, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results